DBV Technologies is a global clinical stage biopharmaceutical company that develops epicutaneous immunotherapy for food allergies and other immunological diseases. Self-described.

DBV Technologies

DBV Technologies | 16,493 followers on LinkedIn. On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™ | DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.

We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.

This mission drives our commitment to the advancement of treatments for patients and their families.

Vincent DIOSZEGHY

LifeSci Advisors-LS Associates

Will de Groot

Freelance Photographer at Thomas Raffoux Photography

Thomas Raffoux

Chief Medical Officer at Sitryx Therapeutics

Ravi Rao

DBV is proud to sponsor FAACT, Food Allergy & Anaphylaxis Connection Team 's Digital Influencer Summit and tenth annual Global Food Industry and Research Summit. We look forward to connecting with peers to explore how to safely meet the needs of the #FoodAllergy community. Stop by our booth to learn more: https://bit.ly/40CQskp

Today, we reported financial results for the third quarter of 2024. Read the full press release here: https://bit.ly/4hEPzhe

We look forward to joining our #FoodAllergy peers at the upcoming American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, where we will be hosting a product theater on Saturday, October 26. Visit us at our booth to learn more about our potential treatment for those with peanut allergy. Details here: https://bit.ly/3NGNPWZ

We are pleased to announce positive regulatory updates for our investigational product, the Viaskin® Peanut Patch, including guidance on a pathway for Accelerated Approval for toddlers ages 1-3 with #PeanutAllergy . Join our conference call at 5pm ET for more: https://bit.ly/4hfTfpC

Our CMO, Pharis Mohideen , participated in a panel at FARE Neighborhoods Day about using data & research to navigate the landscapes of our neighborhoods to create more equitable futures for those with #FoodAllergies . We're grateful for the opportunity to participate in inspiring dialogue to move toward a more inclusive and healthy future for all.

Our team had the pleasure of connecting with members of the #allergy community for Allergy & Asthma Network 's annual #CorporateCouncil meeting. It was great to come together and discuss ways to empower patients and create a healthier future for all.

🔬 Our innovative technology platform merges science and technology to change the way we think about #allergy treatment. It allows us to explore the potential of the Viaskin® patch and epicutaneous immunotherapy for children with #PeanutAllergy . Learn more here: https://bit.ly/4b5svUE

In case you missed it, KSTP Minnesota explores the development of our investigational pediatric #PeanutAllergy treatment with Dr. Doug McMahon of the Asthma & Allergy Center of Minnesota and our CMO, Dr. Pharis Mohideen, featuring insights from a mother of a peanut-allergic child. Watch here to learn more: https://bit.ly/4guSbhe

Don't miss our lunch symposium at this year's World Allergy Congress. We will discuss our work to advance our lead candidate for the treatment of #PeanutAllergy . Learn more about the congress here: https://bit.ly/3MO4ub1 World Allergy Organization

We are proud to share that we've completed screening for our VITESSE Phase 3 #ClinicalTrial for children ages 4-7 with a #PeanutAllergy . We look forward to further advancing our clinical development program. Read more in our press release: https://bit.ly/4gxNxiD

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBV Technologies S.A.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 9, 2024 10:05 PM	d30e9160
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 9, 2024 10:05 PM	eb03e9d6
crunchbase trigger	general	Nov 9, 2024 10:05 PM	6cdce654
crunchbase profile	general
li profile	general	Nov 9, 2024 10:05 PM	1d0e89d0
translate crunchbase fundingrounds	general
peers	general	Nov 9, 2024 10:05 PM	fdc114c8
news basic	general	Nov 9, 2024 10:05 PM	a8c0dce8
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:DBV-TECHNOLOGIES

DBV Technologies

Last Close

0.53

21/11 16:37

Market Cap

73.81M

Beta: -

Volume Today

237.26K

Avg: -